

**WRITTEN QUESTION TO THE MINISTER FOR HEALTH AND SOCIAL SERVICES  
BY DEPUTY L.M.C. DOUBLET OF ST. SAVIOUR  
QUESTION SUBMITTED ON MONDAY 24th MARCH 2025  
ANSWER TO BE TABLED ON MONDAY 31st MARCH 2025**

**Question**

“Will the Minister provide information on the rates of prostate cancer in Jersey compared to the UK for the past 5 years and advise –

- (a) whether Jersey follows the National Institute for Health and Care Excellence (NICE) guidelines for the treatment of prostate cancer; and
- (b) whether Abiraterone, a drug available in Scotland and Wales for high-risk prostate cancer patients whose cancer has not yet spread, is available to patients in Jersey, and if not, why not?”

**Answer**

- (a) Jersey follows, as a minimum, the NICE clinical guidelines for prostate cancer diagnosis and treatment. These evidence-based standards ensure that patients receive care consistent with best practice across England. In addition to NICE-approved treatments, Jersey also follows recommendations from the Cancer Drugs Fund (CDF).
- (b) Abiraterone has been available to eligible Jersey patients for over five years, in line with best practice in England and NICE guidelines. High risk patients with localised disease, that would benefit from Abiraterone or newer **androgen receptor inhibitors**, like **enzalutamide** and **apalutamide**, are offered these. We have a process that is called Individual Patient Funding Request (IPFR) which allows us to request treatment that are outside of NICE guidelines

**Additional information**

- Approximately 62 men are diagnosed with prostate cancer each year in Jersey.
- The age-standardised incidence rate in Jersey (193.3/100,000) is slightly higher than in England (~186/100,000).
- The median age at diagnosis for prostate cancer in Jersey is 71 years, which is identical to England’s average.
- Over 90% of cases are diagnosed in men aged 60 and above, consistent with national trends.
- Jersey’s slightly higher prostate cancer incidence rate compared to England most likely reflects enhanced case detection, particularly due to greater PSA testing uptake, improved access to diagnostics, and earlier diagnosis through routine monitoring by primary care.
- What is the Cancer Drug Fund? The CDF enables early access to innovative cancer treatments that have demonstrated significant clinical benefit but are still undergoing full NICE appraisal. This approach ensures patients can benefit from promising new therapies without unnecessary delay.

[Channel Islands Cancer Report](#)